Etiology and Pathogenesis of Psoriatic Arthritis

Rheumatic Disease Clinics of North America

Volumn 41, Issue 4, 2015, Pages 643-663

  Barnas, Jennifer L ^a   Ritchlin, Christopher T ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Dactylitis; Enthesitis; IL 17; IL 23; Inflammatory arthritis; Psoriasis; Psoriatic arthritis; Spondyloarthropathy

Indexed keywords

APREMILAST; BONE MORPHOGENETIC PROTEIN; BRODALUMAB; DICKKOPF 1 PROTEIN; HLA ANTIGEN CLASS 1; HLA B27 ANTIGEN; HLA C ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 23; IXEKIZUMAB; LEPTIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SECUKINUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; WNT PROTEIN;

ANKYLOSIS; BONE DESTRUCTION; BONE EROSION; BONE MARROW EDEMA; CYTOKINE PRODUCTION; DACTYLITIS; DYSBIOSIS; ENTHESITIS; GENETIC RISK; HUMAN; IMMUNOPATHOLOGY; MECHANICAL STRESS; MICROBIOME; NAIL PSORIASIS; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SACROILIITIS; STREPTOCOCCAL PHARYNGITIS; SYNOVITIS; TH17 CELL; UVEITIS; ADVERSE EFFECTS; ARTHRITIS, PSORIATIC; ENVIRONMENTAL EXPOSURE; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; RISK FACTOR;

ARTHRITIS, PSORIATIC; ENVIRONMENTAL EXPOSURE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, INNATE; RISK FACTORS;

EID: 84945491539     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2015.07.006     Document Type: Review

References (121)

1. Wright V. Psoriasis and arthritis. Ann Rheum Dis 1956, 15(4):348-356.
2. Moll J.M., Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973, 3(1):55-78.
3. Moll J.M., Johnson G., Wright V. Psoriatic arthritis: a unique family. Rheumatol Rehabil 1974, 13(3):154-157.
4. Chandran V., Schentag C.T., Brockbank J.E., et al. Familial aggregation of psoriatic arthritis. Ann Rheum Dis 2009, 68(5):664-667.
5. Rigby A.S., Voelm L., Silman A.J. Epistatic modeling in rheumatoid arthritis: an application of the Risch theory. Genet Epidemiol 1993, 10(5):311-320.
6. Karason A., Love T.J., Gudbjornsson B. A strong heritability of psoriatic arthritis over four generations-the reykjavik psoriatic arthritis study. Rheumatology 2009, 48(11):1424-1428.
7. Trembath R.C., Clough R.L., Rosbotham J.L., et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 1997, 6(5):813-820.
8. Gudjonsson J.E., Karason A., Runarsdottir E.H., et al. Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients-an analysis of 1019 HLA-C- and HLA-B-typed patients. J Invest Dermatol 2006, 126(4):740-745.
9. Okada Y., Han B., Tsoi L.C., et al. Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes. Am J Hum Genet 2014, 95(2):162-172.
10. Bowes J., Budu-Aggrey A., Huffmeier U., et al. Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. Nat Commun 2015, 6:6046.
11. Castillo-Gallego C., Aydin S.Z., Emery P., et al. Magnetic resonance imaging assessment of axial psoriatic arthritis: extent of disease relates to HLA-B27. Arthritis Rheum 2013, 65(9):2274-2278.
12. Winchester R., Minevich G., Steshenko V., et al. HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. Arthritis Rheum 2012, 64(4):1134-1144.
13. Telfer N.R., Chalmers R.J., Whale K., et al. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol 1992, 128(1):39-42.
14. Valdimarsson H., Sigmundsdottir H., Jonsdottir I. Is psoriasis induced by streptococcal superantigens and maintained by M-protein-specific T cells that cross-react with keratin? Clinical and experimental immunology. Clin Exp Immunol 1997, 107(Suppl 1):21-24.
15. Diluvio L., Vollmer S., Besgen P., et al. Identical TCR beta-chain rearrangements in streptococcal angina and skin lesions of patients with psoriasis vulgaris. J Immunol 2006, 176(11):7104-7111.
16. Thorleifsdottir R.H., Sigurdardottir S.L., Sigurgeirsson B., et al. Improvement of psoriasis after tonsillectomy is associated with a decrease in the frequency of circulating T cells that recognize streptococcal determinants and homologous skin determinants. J Immunol 2012, 188(10):5160-5165.
17. Besgen P., Trommler P., Vollmer S., et al. Ezrin, maspin, peroxiredoxin 2, and heat shock protein 27: potential targets of a streptococcal-induced autoimmune response in psoriasis. J Immunol 2010, 184(9):5392-5402.
18. Hsieh J., Kadavath S., Efthimiou P. Can traumatic injury trigger psoriatic arthritis? A review of the literature. Clin Rheumatol 2014, 33(5):601-608.
19. Cox M.J., Cookson W.O., Moffatt M.F. Sequencing the human microbiome in health and disease. Hum Mol Genet 2013, 22(R1):R88-R94.
20. Naik S., Bouladoux N., Linehan J.L., et al. Commensal-dendritic-cell interaction specifies a unique protective skin immune signature. Nature 2015, 520(7545):104-108.
21. Takemoto A., Cho O., Morohoshi Y., et al. Molecular characterization of the skin fungal microbiome in patients with psoriasis. J Dermatol 2015, 42(2):166-170.
22. Alekseyenko A.V., Perez-Perez G.I., De Souza A., et al. Community differentiation of the cutaneous microbiota in psoriasis. Microbiome 2013, 1(1):31.
23. Nibali L., Henderson B., Sadiq S.T., et al. Genetic dysbiosis: the role of microbial insults in chronic inflammatory diseases. J Oral Microbiol 2014, 6. 10.3402/jom.v6.22962.
24. Scarpa R., Manguso F., D'Arienzo A., et al. Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol 2000, 27(5):1241-1246.
25. Li W.Q., Han J.L., Chan A.T., et al. Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women. Ann Rheum Dis 2013, 72(7):1200-1205.
26. Scher J.U., Ubeda C., Artacho A., et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol 2015, 67(1):128-139.
27. Brestoff J.R., Artis D. Immune regulation of metabolic homeostasis in health and disease. Cell 2015, 161(1):146-160.
28. Versini M., Jeandel P.Y., Rosenthal E., et al. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev 2014, 13(9):981-1000.
29. Wang Y., Chen J., Zhao Y., et al. Psoriasis is associated with increased levels of serum leptin. Br J Dermatol 2008, 158(5):1134-1135.
30. Coimbra S., Oliveira H., Reis F., et al. Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J Eur Acad Dermatol Venereol 2010, 24(12):1386-1394.
31. Johnston A., Arnadottir S., Gudjonsson J.E., et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol 2008, 159(2):342-350.
32. Takahashi H., Tsuji H., Honma M., et al. Increased plasma resistin and decreased omentin levels in Japanese patients with psoriasis. Arch Dermatol Res 2013, 305(2):113-116.
33. Setty A.R., Curhan G., Choi H.K. Obesity, waist circumference, weight change, and the risk of psoriasis in women: nurses' health study II. Arch Intern Med 2007, 167(15):1670-1675.
34. Armstrong A.W., Harskamp C.T., Armstrong E.J. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes 2012, 2:e54.
35. Love T.J., Zhu Y., Zhang Y., et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis 2012, 71(8):1273-1277.
36. Edson-Heredia E., Zhu B., Lefevre C., et al. Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink. J Eur Acad Dermatol Venereol 2014, 29(5):955-963.
37. Naldi L., Conti A., Cazzaniga S., et al. Diet and physical exercise in psoriasis: a randomized controlled trial. Br J Dermatol 2014, 170(3):634-642.
38. Jensen P., Zachariae C., Christensen R., et al. Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatol 2013, 149(7):795-801.
39. Farias M.M., Achurra P., Boza C., et al. Psoriasis following bariatric surgery: clinical evolution and impact on quality of life on 10 patients. Obes Surg 2012, 22(6):877-880.
40. Hossler E.W., Wood G.C., Still C.D., et al. The effect of weight loss surgery on the severity of psoriasis. Br J Dermatol 2013, 168(3):660-661.
41. Al-Mutairi N., Nour T. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial. Expert Opin Biol Ther 2014, 14(6):749-756.
42. Mosmann T.R., Cherwinski H., Bond M.W., et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986, 136(7):2348-2357.
43. Park H., Li Z., Yang X.O., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6(11):1133-1141.
44. Harrington L.E., Hatton R.D., Mangan P.R., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6(11):1123-1132.
45. Rouvier E., Luciani M.F., Mattei M.G., et al. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 1993, 150(12):5445-5456.
46. Manel N., Unutmaz D., Littman D.R. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 2008, 9(6):641-649.
47. Lee Y.K., Turner H., Maynard C.L., et al. Late developmental plasticity in the T helper 17 lineage. Immunity 2009, 30(1):92-107.
48. Annunziato F., Cosmi L., Santarlasci V., et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007, 204(8):1849-1861.
49. Eyerich S., Eyerich K., Pennino D., et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009, 119(12):3573-3585.
50. Leipe J., Grunke M., Dechant C., et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 2010, 62(10):2876-2885.
51. Menon B., Gullick N.J., Walter G.J., et al. Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol 2014, 66(5):1272-1281.
52. Cai Y., Shen X., Ding C., et al. Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation. Immunity 2011, 35(4):596-610.
53. Witte E., Kokolakis G., Witte K., et al. IL-19 is a component of the pathogenetic IL-23/IL-17 cascade in psoriasis. J Invest Dermatol 2014, 134(11):2757-2767.
54. Li N., Yamasaki K., Saito R., et al. Alarmin function of cathelicidin antimicrobial peptide LL37 through IL-36γ induction in human epidermal keratinocytes. J Immunol 2014, 193(10):5140-5148.
55. Papp K.A., Leonardi C., Menter A., et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012, 366(13):1181-1189.
56. Krueger J.G., Ferris L.K., Menter A., et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2015, 136(1):116-124.e7.
57. Leonardi C., Matheson R., Zachariae C., et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012, 366(13):1190-1199.
58. Tan A.L., Benjamin M., Toumi H., et al. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis-a high-resolution MRI and histological study. Rheumatology 2007, 46(2):253-256.
59. Carney C.K., Cantrell W., Elewski B.E. Nail psoriasis: a review of current topical and systemic therapies. Adv Psor Inflamm Skin Dis 2010, 1(3):89-97.
60. Radtke M.A., Beikert F.C., Augustin M. Nail psoriasis-a treatment challenge. J Dtsch Dermatol Ges 2013, 11(3):203-219. [quiz: 20].
61. Healy P.J., Groves C., Chandramohan M., et al. MRI changes in psoriatic dactylitis-extent of pathology, relationship to tenderness and correlation with clinical indices. Rheumatology 2008, 47(1):92-95.
62. Benjamin M., Moriggl B., Brenner E., et al. The "enthesis organ" concept: why enthesopathies may not present as focal insertional disorders. Arthritis Rheum 2004, 50(10):3306-3313.
63. Siegel E.L., Orbai A.M., Ritchlin C.T. Targeting extra-articular manifestations in PsA: a closer look at enthesitis and dactylitis. Curr Opin Rheumatol 2015, 27(2):111-117.
64. Paramarta J.E., van der Leij C., Gofita I., et al. Peripheral joint inflammation in early onset spondyloarthritis is not specifically related to enthesitis. Ann Rheum Dis 2014, 73(4):735-740.
65. Jacques P., Lambrecht S., Verheugen E., et al. Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann Rheum Dis 2014, 73(2):437-445.
66. Sherlock J.P., Joyce-Shaikh B., Turner S.P., et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat(+) CD3(+)CD4(-)CD8(-) entheseal resident T cells. Nat Med 2012, 18(7):1069-1076.
67. Ferguson E.G., Coates L.C. Optimisation of rheumatology indices: dactylitis and enthesitis in psoriatic arthritis. Clin Exp Rheumatol 2014, 32(5 Suppl 85):S-113-S-117.
68. Braem K., Carter S., Lories R.J. Spontaneous arthritis and ankylosis in male DBA/1 mice: further evidence for a role of behavioral factors in "stress-induced arthritis". Biol Proced Online 2012, 14(1):10.
69. Lories R.J., Matthys P., de Vlam K., et al. Ankylosing enthesitis, dactylitis, and onychoperiostitis in male DBA/1 mice: a model of psoriatic arthritis. Ann Rheum Dis 2004, 63(5):595-598.
70. Baeten D., Demetter P., Cuvelier C., et al. Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis 2000, 59(12):945-953.
71. van Kuijk A.W., Reinders-Blankert P., Smeets T.J., et al. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 2006, 65(12):1551-1557.
72. Kruithof E., Baeten D., De Rycke L., et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005, 7(3):R569-R580.
73. Celis R., Planell N., Fernandez-Sueiro J.L., et al. Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features. Arthritis Res Ther 2012, 14(2):R93.
74. Raychaudhuri S.P., Raychaudhuri S.K., Genovese M.C. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem 2012, 359(1-2):419-429.
75. Hueber A.J., Asquith D.L., Miller A.M., et al. Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 2010, 184(7):3336-3340.
76. van Baarsen L.G., Lebre M.C., van der Coelen D., et al. Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?. Arthritis Res Ther 2014, 16(4):426.
77. Finzel S., Ohrndorf S., Englbrecht M., et al. A detailed comparative study of high-resolution ultrasound and micro-computed tomography for detection of arthritic bone erosions. Arthritis Rheum 2011, 63(5):1231-1236.
78. Herman S., Muller R.B., Kronke G., et al. Induction of osteoclast-associated receptor, a key osteoclast costimulation molecule, in rheumatoid arthritis. Arthritis Rheum 2008, 58(10):3041-3050.
79. Lam J., Takeshita S., Barker J.E., et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000, 106(12):1481-1488.
80. Sato K., Suematsu A., Okamoto K., et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006, 203(12):2673-2682.
81. Kikuta J., Wada Y., Kowada T., et al. Dynamic visualization of RANKL and Th17-mediated osteoclast function. J Clin Invest 2013, 123(2):866-873.
82. Ritchlin C.T., Haas-Smith S.A., Li P., et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003, 111(6):821-831.
83. Anandarajah A.P., Schwarz E.M., Totterman S., et al. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis. Ann Rheum Dis 2008, 67(3):296-301.
84. Freeston J.E., Coates L.C., Helliwell P.S., et al. Is there subclinical enthesitis in early psoriatic arthritis? A clinical comparison with power doppler ultrasound. Arthritis Care Res 2012, 64(10):1617-1621.
85. Lories R.J., Luyten F.P. Bone morphogenetic protein signaling in joint homeostasis and disease. Cytokine Growth Factor Rev 2005, 16(3):287-298.
86. Pacheco-Tena C., Perez-Tamayo R., Pineda C., et al. Bone lineage proteins in the entheses of the midfoot in patients with spondyloarthritis. J Rheumatol 2015, 42(4):630-637.
87. Semenov M., Tamai K., He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 2005, 280(29):26770-26775.
88. Baron R., Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 2013, 19(2):179-192.
89. Vincent C., Findlay D.M., Welldon K.J., et al. Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J bone miner Res 2009, 24(8):1434-1449.
90. Xiong L., Jung J.U., Wu H., et al. Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption. Proc Natl Acad Sci U S A 2015, 112(11):3487-3492.
91. Mao B., Wu W., Davidson G., et al. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 2002, 417(6889):664-667.
92. Glass D.A., Bialek P., Ahn J.D., et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cel 2005, 8(5):751-764.
93. Heiland G.R., Zwerina K., Baum W., et al. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis 2010, 69(12):2152-2159.
94. Daoussis D., Liossis S.N., Solomou E.E., et al. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 2010, 62(1):150-158.
95. Wanders A., Heijde D., Landewe R., et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005, 52(6):1756-1765.
96. Hreggvidsdottir H.S., Noordenbos T., Baeten D.L. Inflammatory pathways in spondyloarthritis. Mol Immunol 2014, 57(1):28-37.
97. Notley C.A., Inglis J.J., Alzabin S., et al. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med 2008, 205(11):2491-2497.
98. Alzabin S., Abraham S.M., Taher T.E., et al. Incomplete response of inflammatory arthritis to TNFalpha blockade is associated with the Th17 pathway. Ann Rheum Dis 2012, 71(10):1741-1748.
99. Hull D.N., Williams R.O., Pathan E., et al. Anti-TNF treatment increases circulating Th17 cells similarly in different types of inflammatory arthritis. Clin Exp Immunol 2015, 10.1111/cei.12626.
100. Sieper J., Appel H., Braun J., et al. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum 2008, 58(3):649-656.
101. Kavanaugh A., Mease P.J., Gomez-Reino J.J., et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014, 73(6):1020-1026.
102. Schafer P.H., Parton A., Gandhi A.K., et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010, 159(4):842-855.
103. Mease P.J., Genovese M.C., Greenwald M.W., et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 2014, 370(24):2295-2306.
104. Kavanaugh A., Ritchlin C., Rahman P., et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 2014, 73(6):1000-1006.
105. McInnes I.B., Sieper J., Braun J., et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2014, 73(2):349-356.
106. Letko E., Yeh S., Foster C.S., et al. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology 2015, 122(5):939-948.
107. Cretu D., Liang K., Saraon P., et al. Quantitative tandem mass-spectrometry of skin tissue reveals putative psoriatic arthritis biomarkers. Clin Proteomics 2015, 12(1):1.
108. Yamaguchi Y. Periostin in skin tissue and skin-related diseases. Allergol Int 2014, 63(2):161-170.
109. Zenz R., Eferl R., Kenner L., et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005, 437(7057):369-375.
110. Bardos T., Zhang J., Mikecz K., et al. Mice lacking endogenous major histocompatibility complex class II develop arthritis resembling psoriatic arthritis at an advanced age. Arthritis Rheum 2002, 46(9):2465-2475.
111. Khare S.D., Luthra H.S., David C.S. Spontaneous inflammatory arthritis in HLA-B27 transgenic mice lacking beta 2-microglobulin: a model of human spondyloarthropathies. J Exp Med 1995, 182(4):1153-1158.
112. Yanagisawa H., Richardson J.A., Taurog J.D., et al. Characterization of psoriasiform and alopecic skin lesions in HLA-B27 transgenic rats. Am J Pathol 1995, 147(4):955-964.
113. Ruutu M., Thomas G., Steck R., et al. Beta-glucan triggers spondylarthritis and Crohn's disease-like ileitis in SKG mice. Arthritis Rheum 2012, 64(7):2211-2222.
114. Cook P.W., Brown J.R., Cornell K.A., et al. Suprabasal expression of human amphiregulin in the epidermis of transgenic mice induces a severe, early-onset, psoriasis-like skin pathology: expression of amphiregulin in the basal epidermis is also associated with synovitis. Exp Dermatol 2004, 13(6):347-356.
115. Yamamoto M., Nakajima K., Takaishi M., et al. Psoriatic inflammation facilitates the onset of arthritis in a mouse model. J Invest Dermatol 2015, 135(2):445-453.
116. Rothschild B.M. Primate spondyloarthropathy. Curr Rheumatol Rep 2005, 7(3):173-181.
117. Wang C., Wu L., Bulek K., et al. The psoriasis-associated D10N variant of the adaptor Act1 with impaired regulation by the molecular chaperone hsp90. Nat Immunol 2013, 14(1):72-81.
118. Courtenay J.S., Dallman M.J., Dayan A.D., et al. Immunisation against heterologous type II collagen induces arthritis in mice. Nature 1980, 283(5748):666-668.
119. Adamopoulos I.E., Tessmer M., Chao C.C., et al. IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass. J Immunol 2011, 187(2):951-959.
120. Keffer J., Probert L., Cazlaris H., et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991, 10(13):4025-4031.
121. Hammer R.E., Richardson J.A., Simmons W.A., et al. High prevalence of colorectal cancer in HLA-B27 transgenic F344 rats with chronic inflammatory bowel disease. J Investig Med 1995, 43(3):262-268.